公开(公告)号：US09186337B2

公开(公告)日：2015-11-17

申请号：US13580710

申请日：2011-02-24

Applicant: Jonathan Alleman Baker ,  Matthew Colin Thor Fyfe

Inventor： Jonathan Alleman Baker ,  Matthew Colin Thor Fyfe

IPC: A61K31/131 ,  A61K31/135 ,  A61K31/165 ,  A61K31/15 ,  A61K38/21 ,  A61K45/06 ,  A61K31/137

CPC classification number: A61K31/135 ,  A61K31/131 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

Abstract translation: 本发明提供治疗或预防肝炎病毒科感染和由肝炎病毒科感染引起的疾病。 特别地，本发明提供影响Hepadnaviridae利用宿主细胞机制作为病毒生命周期的一部分的能力的组合物和方法。 本发明涉及干扰病毒利用宿主细胞机制与LSD1抑制剂的正常能力的发现降低HBV复制。 因此，根据本发明的肝炎病毒科感染和肝炎病毒科引起的疾病的治疗和预防包括向需要治疗的个体施用治疗有效量的LSD1抑制剂。 需要治疗的个体可以是人或例如另一种哺乳动物。

公开(公告)号：US20130095067A1

公开(公告)日：2013-04-18

申请号：US13580710

申请日：2011-02-24

Applicant: Jonathan Alleman Baker ,  Matthew Colin Thor Fyfe

Inventor： Jonathan Alleman Baker ,  Matthew Colin Thor Fyfe

IPC: A61K31/135 ,  A61K38/21 ,  A61K31/137 ,  A61K31/131 ,  A61K31/165 ,  A61K45/06

CPC classification number: A61K31/135 ,  A61K31/131 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

Abstract translation: 本发明提供治疗或预防肝炎病毒科感染和由肝炎病毒科感染引起的疾病。 特别地，本发明提供影响Hepadnaviridae利用宿主细胞机制作为病毒生命周期的一部分的能力的组合物和方法。 本发明涉及干扰病毒利用宿主细胞机制与LSD1抑制剂的正常能力的发现降低HBV复制。 因此，根据本发明的肝炎病毒科感染和肝炎病毒科引起的疾病的治疗和预防包括向需要治疗的个体施用治疗有效量的LSD1抑制剂。 需要治疗的个体可以是人或例如另一种哺乳动物。

公开(公告)号：US08207147B2

公开(公告)日：2012-06-26

申请号：US10584025

申请日：2004-12-23

Applicant: Matthew Colin Thor Fyfe ,  Lisa Sarah Gardner ,  John King-Underwood ,  Martin James Procter ,  Chrystelle Marie Rasamison ,  Karen Lesley Schofield ,  Gerard Hugh Thomas

Inventor： Matthew Colin Thor Fyfe ,  Lisa Sarah Gardner ,  John King-Underwood ,  Martin James Procter ,  Chrystelle Marie Rasamison ,  Karen Lesley Schofield ,  Gerard Hugh Thomas

IPC: A61K31/66 ,  A61K31/497 ,  A61K31/4523 ,  C07D401/14 ,  C07F9/02 ,  C07D211/00 ,  C07D413/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04 ,  C07D417/14

Abstract: Compounds of Formula (I), R1-A-V—B—R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.

Abstract translation: 式（I）的化合物，R1-A-V-B-R2; 或其药学上可接受的盐是GPR116的激动剂，并且可用作饱腹感的调节剂，例如， 用于治疗肥胖症和治疗糖尿病。

公开(公告)号：US20110212939A1

公开(公告)日：2011-09-01

申请号：US13003571

申请日：2009-07-10

Applicant: Lisa Sarah Bertram ,  Philip Graham Clarke ,  Graham John Dawson ,  Peter Timothy Fry ,  Matthew Colin Thor Fyfe ,  William Gattrell ,  Revathy Perpetua Jeevaratnam ,  John Keily ,  Thomas Martin Krulle ,  Martin James Procter ,  Chrystelle Marie Rasamison ,  Colin Peter Sambrook-Smith ,  Simon Andrew Swain

Inventor： Lisa Sarah Bertram ,  Philip Graham Clarke ,  Graham John Dawson ,  Peter Timothy Fry ,  Matthew Colin Thor Fyfe ,  William Gattrell ,  Revathy Perpetua Jeevaratnam ,  John Keily ,  Thomas Martin Krulle ,  Martin James Procter ,  Chrystelle Marie Rasamison ,  Colin Peter Sambrook-Smith ,  Simon Andrew Swain

IPC: A61K31/397 ,  C07D401/04 ,  A61K31/506 ,  C07D401/14 ,  A61K31/4965 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/4709 ,  A61K31/517 ,  A61P3/00

CPC classification number: C07D401/12 ,  C07D295/205 ,  C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.

Abstract translation: 式（I）化合物或其药学上可接受的盐是GPCR（GPR119）激动剂，可用于治疗糖尿病和肥胖症。

公开(公告)号：US20110195994A1

公开(公告)日：2011-08-11

申请号：US13003569

申请日：2009-07-10

Applicant: Lisa Sarah Bertram ,  Matthew Colin Thor Fyfe

Inventor： Lisa Sarah Bertram ,  Matthew Colin Thor Fyfe

IPC: A61K31/454 ,  C07D401/04 ,  A61P3/00 ,  A61P9/12

CPC classification number: C07D413/04

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.

Abstract translation: 式（I）化合物或其药学上可接受的盐是GPCR激动剂，可用于治疗糖尿病和肥胖症。

公开(公告)号：US20100022591A1

公开(公告)日：2010-01-28

申请号：US12522018

申请日：2008-01-04

Applicant: Lisa Sarah Bertram ,  Matthew Colin Thor Fyfe ,  Revathy Perpetua Jeevaratnam ,  John Keily ,  Simon Andrew Swain

Inventor： Lisa Sarah Bertram ,  Matthew Colin Thor Fyfe ,  Revathy Perpetua Jeevaratnam ,  John Keily ,  Simon Andrew Swain

IPC: A61K31/454 ,  C07D401/04 ,  A61P3/10 ,  A61P9/10 ,  A61P3/04

CPC classification number: C07D413/04

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

Abstract translation: 式（I）化合物或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。

公开(公告)号：US20090221824A1

公开(公告)日：2009-09-03

申请号：US11573471

申请日：2005-08-12

Applicant: Paul Howard Briner ,  Matthew Colin Thor Fyfe ,  John Paul Madeley ,  Peter John Murray ,  Martin James Procter ,  Felix Spindler

Inventor： Paul Howard Briner ,  Matthew Colin Thor Fyfe ,  John Paul Madeley ,  Peter John Murray ,  Martin James Procter ,  Felix Spindler

IPC: C07D405/12 ,  C07D315/00 ,  C07D417/12

CPC classification number: C07D405/12 ,  C07D309/04 ,  C07D417/12

Abstract: A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives.

Abstract translation: 一种制备包含2-取代的丙烯酸衍生物的对映选择性氢化的化合物的方法。

公开(公告)号：US20090221639A1

公开(公告)日：2009-09-03

申请号：US12225961

申请日：2007-04-05

Applicant: Lisa Sarah Bertram ,  Matthew Colin Thor Fyfe ,  Martin James Procter ,  Geoffrey Martyn Williams

Inventor： Lisa Sarah Bertram ,  Matthew Colin Thor Fyfe ,  Martin James Procter ,  Geoffrey Martyn Williams

IPC: A61K31/4545 ,  C07D413/02 ,  A61K31/454 ,  C07D401/02 ,  A61P3/04 ,  A61P3/10 ,  A61P3/00

CPC classification number: C07D413/14 ,  C07D413/12

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.

Abstract translation: 式（I）化合物或其药学上可接受的盐是GPR119的激动剂，可用作饱腹感调节剂，例如， 用于治疗肥胖症和治疗糖尿病。

公开(公告)号：US20090203676A1

公开(公告)日：2009-08-13

申请号：US11922826

申请日：2006-06-30

Applicant: Oscar Barba ,  Stuart Edward Bradley ,  Matthew Colin Thor Fyfe ,  Lisa Sarah Bertram ,  William Gattrell ,  Martin James Procter ,  Chrystelle Marie Rasamison ,  Simon Andrew Swain

Inventor： Oscar Barba ,  Stuart Edward Bradley ,  Matthew Colin Thor Fyfe ,  Lisa Sarah Bertram ,  William Gattrell ,  Martin James Procter ,  Chrystelle Marie Rasamison ,  Simon Andrew Swain

IPC: A61K31/496 ,  C07D401/06 ,  C07D401/14 ,  C07D413/14 ,  C07D497/08 ,  A61K31/551 ,  A61K31/454 ,  A61P3/04 ,  A61P3/10 ,  A61P3/00

CPC classification number: C07D401/04 ,  C07D211/20 ,  C07D211/26 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D487/08

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

Abstract translation: 式（I）化合物或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。

公开(公告)号：US20090099227A1

公开(公告)日：2009-04-16

申请号：US11794220

申请日：2005-12-23

Applicant: Matthew Colin Thor Fyfe ,  Gerard Hugh Thomas ,  Lisa Sarah Bertram ,  Stuart Edward Bradley ,  William Gattrell ,  Chrystelle Marie Rasamison ,  Vilasben Kanji Shah

Inventor： Matthew Colin Thor Fyfe ,  Gerard Hugh Thomas ,  Lisa Sarah Bertram ,  Stuart Edward Bradley ,  William Gattrell ,  Chrystelle Marie Rasamison ,  Vilasben Kanji Shah

IPC: A61K31/4355 ,  C07D491/048

CPC classification number: C07D471/04 ,  C07D491/04 ,  C07D495/04

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

Abstract translation: 式（I）化合物或其药学上可接受的盐或N-氧化物是GPR116的激动剂，可用于治疗肥胖症和治疗糖尿病。